Kowa Pharmaceuticals America announces agreement with CymaBay Therapeutics to license gout compound
Client(s) Kowa Company, Ltd.
Jones Day advised Kowa Company, Ltd. and its subsidiary Kowa Pharmaceuticals America, Inc. in a license agreement with CymaBay Therapeutics for exclusive U.S. rights to Arhalofenate, a compound in late stage clinical development for the treatment of gout.